Exhibit 8.1

Wells Fargo & Company,

    420 Montgomery Street,

        San Francisco, California 94104.

Ladies and Gentlemen:

We have acted as special tax counsel to Wells Fargo & Company, a Delaware corporation (the “Company”), in connection with the issuance of (i) $4,440,000 aggregate face amount of Medium-Term Notes, Series K, Principal at Risk Securities Linked to the MSCI EAFE Index^® as described in the Company’s Pricing Supplement No. 400 dated January 24, 2014 (“Pricing Supplement 400”) to the Prospectus Supplement dated April 13, 2012 (the “Prospectus Supplement”) and the Prospectus dated April 13, 2012 (the “Prospectus”) contained in the Registration Statement on Form S-3, File No. 333-180728 (the “Registration Statement”) and (ii) $595,000 aggregate face amount of Medium-Term Notes, Series K, Principal at Risk Securities Linked to the S&P 500^® Index due January 31, 2019 as described in the Company’s Pricing Supplement No. 394 dated January 28, 2014 (“Pricing Supplement 394”) to Product Supplement No. 6 dated July 13, 2012, the Prospectus Supplement and the Prospectus contained in the Registration Statement. We hereby confirm our opinion as set forth under the headings “United States Federal Income Tax Considerations” in Pricing Supplement 400 and “Material Tax Consequences” in Pricing Supplement 394.

We hereby consent to the reference to us under the headings “United States Federal Income Tax Considerations” in Pricing Supplement 400 and “Material Tax Consequences” in Pricing Supplement 394 and to the filing of this opinion as an exhibit to a Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission and thereby incorporated by reference into the Company’s Registration Statement. In giving such consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.